Cetuximab monotherapy in advanced cervical cancer: A retrospective study with five patients

Archives of Gynecology and Obstetrics

Volumn 283, Issue 1, 2011, Pages 109-113

  Hertlein, Linda ^a   Lenhard, Miriam ^a   Kirschenhofer, Angela ^a   Kahlert, Steffen ^a   Mayr, Doris ^a   Burges, Alexander ^a   Friese, Klaus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Advanced cervical cancer; Cetuximab; EGFR antibody

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; IFOSFAMIDE; PACLITAXEL;

ACNE; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG ERUPTION; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ACNEIFORM ERUPTIONS; ADENOCARCINOMA; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 78751582338     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-010-1389-1     Document Type: Article

References (16)

1. P Bonomi JA Blessing FB Stehman PJ DiSaia L Walton FJ Major 1985 Randomized trial of three cisplatin dose schedules in squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 3 8 1079 1085 1:STN:280:DyaL2M3mtlOmsg%3D%3D 3894589
2. PG Rose JA Blessing DM Gershenson R McGehee 1999 Paclitaxel and cisplatin as firstline therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 17 9 2676 2680 1:CAS:528:DyaK1MXmtlWrurc%3D 10561341
3. AF Burnett LD Roman AA Garcia LI Muderspach KR Brader CP Morrow 2000 A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix Gynecol Oncol 76 1 63 66 1:CAS:528:DC%2BD3cXosFWq 10.1006/gyno.1999.5657 10620443 (Pubitemid 30048321)
4. HJ Long 3rd BN Bundy EC Grendys Jr, et al. 2005 Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study J Clin Oncol 23 21 4626 4633 1:CAS:528:DC%2BD2MXotFarsrk%3D 10.1200/JCO.2005.10.021 15911865 (Pubitemid 46224065)
5. NI Goldstein M Prewett K Zuklys P Rockwell J Mendelsohn 1995 Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model Clin Cancer Res 1 11 1311 1318 1:CAS:528: DyaK28XjvF2gsA%3D%3D 9815926
6. JA Bonner PM Harari J Giralt, et al. 2006 Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck N Engl J Med 354 6 567 578 1:CAS:528:DC%2BD28Xhtleksbs%3D 10.1056/NEJMoa053422 16467544 (Pubitemid 43209104)
7. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 7 1201 1208 1:CAS:528:DC%2BD2cXpsVGktLw%3D 10.1200/JCO.2004.10.182 14993230 (Pubitemid 41079832)
8. JB Vermorken J Trigo R Hitt, et al. 2007 Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy J Clin Oncol 25 16 2171 2177 1:CAS:528:DC%2BD2sXnsVShtrk%3D 10.1200/JCO.2006.06. 7447 17538161 (Pubitemid 46954639)
9. S Bellone G Frera G Landolfi, et al. 2007 Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecol Oncol 106 3 513 520 1:CAS:528:DC%2BD2sXhtVSjsrnE 10.1016/j.ygyno.2007.04.028 17540437 (Pubitemid 47302461)
10. Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft e.V. (DKG) und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG); AGO Kommission Uterus Diagnostik und Therapie des Zervixkarzinoms DKG 2008:032/033 (S2 k)
11. G Alvarez A Perry BR Tan HL Wang 2006 Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification Mod Pathol 19 7 942 949 1:CAS:528:DC%2BD28Xls1KitLw%3D 10.1038/modpathol.3800608 16648870
12. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumours J Natl Cancer Inst 92 3 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437 (Pubitemid 30099779)
13. D Pfeiffer B Stellwag A Pfeiffer P Borlinghaus W Meier P Scheidel 1989 Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix Gynecol Oncol 33 2 146 150 1:STN:280:DyaL1M7pslSitQ%3D%3D 10.1016/0090-8258(89)90540-4 2784777 (Pubitemid 19112903)
14. WJ Gullick JJ Marsden N Whittle B Ward L Bobrow MD Waterfield 1986 Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas Cancer Res 46 1 285 292 1:CAS:528:DyaL28XmtlalsA%3D%3D 2998607
15. JE Kurtz AC Hardy-Bessard M Deslandres, et al. 2009 Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial Gynecol Oncol 113 1 16 20 1:CAS:528:DC%2BD1MXjsVKrsrg%3D 10.1016/j.ygyno.2008.12.040 19232434
16. BJ Monk MW Sill RA Burger HJ Gray TE Buekers LD Roman 2009 Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study J Clin Oncol 27 7 1069 1074 1:CAS:528:DC%2BD1MXktVCju7o%3D 10.1200/JCO.2008.18.9043 19139430